Detectable clonal mosaicism in the human genome

Seminars in Hematology

Volumn 50, Issue 4, 2013, Pages 348-359

  Machiela, Mitchell J ^a   Chanock, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN GENOME; MOSAICISM; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE FACTORS; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MOSAICISM; NEOPLASMS; RISK FACTORS;

EID: 84887532678     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.09.001     Document Type: Article

References (102)

1. Zlotnikoff M. A Human Mosaic. J Heredity 1945, 36:163-168.
2. Strachan T, Read AP, Strachan T. Human molecular genetics. 4th ed. New York. Garland Science; 2011. xxv, p. 781.
3. Larsson N.G. Somatic mitochondrial DNA mutations in mammalian aging. Annu Rev Biochem 2010, 79:683-706.
4. Bianchi N.O., Bianchi M.S., Richard S.M. Mitochondrial genome instability in human cancers. Mutat Res 2001, 488:9-23.
5. Taylor R.W., Turnbull D.M. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005, 6:389-402.
6. Schwab A.L., Tuohy T.M., Condie M., et al. Gonadal mosaicism and familial adenomatous polyposis. Fam Cancer 2008, 7:173-177.
7. Davidson S., Leshanski L., Rennert G., et al. Maternal mosaicism for a second mutational event--a novel deletion--in a familial adenomatous polyposis family harboring a new germ-line mutation in the alternatively spliced-exon 9 region of APC. Hum Mutat 2002, 19:83-84.
8. Niu D.M., Huang J.Y., Li H.Y., et al. Paternal gonadal mosaicism of NIPBL mutation in a father of siblings with Cornelia de Lange syndrome. Prenat Diagn 2006, 26:1054-1057.
9. Depienne C., Arzimanoglou A., Trouillard O., et al. Parental mosaicism can cause recurrent transmission of SCN1A mutations associated with severe myoclonic epilepsy of infancy. Hum Mutat 2006, 27:389.
10. Gennaro E., Santorelli F.M., Bertini E., et al. Somatic and germline mosaicisms in severe myoclonic epilepsy of infancy. Biochem Biophys Res Commun 2006, 341:489-493.
11. Lund A.M., Nicholls A.C., Schwartz M., et al. Parental mosaicism and autosomal dominant mutations causing structural abnormalities of collagen I are frequent in families with osteogenesis imperfecta type III/IV. Acta Paediatr 1997, 86:711-718.
12. Somprasit C., Aguinaga M., Cisneros P.L., et al. Paternal gonadal mosaicism detected in a couple with recurrent abortions undergoing PGD: FISH analysis of sperm nuclei proves valuable. Reprod Biomed Online 2004, 9:225-230.
13. Jacobs K.B., Yeager M., Zhou W., et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 2012, 44:651-658.
14. Laurie C.C., Laurie C.A., Rice K., et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012, 44:642-650.
15. Rodriguez-Santiago B., Malats N., Rothman N., et al. Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. Am J Hum Genet 2010, 87:129-138.
16. Youssoufian H., Pyeritz R.E. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet 2002, 3:748-758.
17. Wang K, Bucan M. Copy number variation detection via high-density snp genotyping. CSH Protoc. 2008:3;1-6.
18. Pique-Regi R., Caceres A., Gonzalez J.R. R-Gada: a fast and flexible pipeline for copy number analysis in association studies. BMC Bioinformatics 2010, 11:380.
19. Gonzalez J.R., Rodriguez-Santiago B., Caceres A., et al. A fast and accurate method to detect allelic genomic imbalances underlying mosaic rearrangements using SNP array data. BMC Bioinformatics 2011, 12:166.
20. Schick U.M., McDavid A., Crane P.K., et al. Confirmation of the reported association of clonal chromosomal mosaicism with an increased risk of incident hematologic cancer. PLoS One 2013, 8:e59823.
21. Forsberg L.A., Rasi C., Razzaghian H.R., et al. Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet 2012, 90:217-228.
22. Kehrer-Sawatzki H., Cooper D.N. Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes?. J Med Genet 2008, 45:622-631.
23. Papavassiliou P., York T.P., Gursoy N., et al. The phenotype of persons having mosaicism for trisomy 21/Down syndrome reflects the percentage of trisomic cells present in different tissues. Am J Med Genet A 2009, 149A:573-583.
24. Grubeck-Loebenstein B. Changes in the aging immune system. Biologicals 1997, 25(2):205-208.
25. Geiger H., de Haan G., Florian M.C. The ageing haematopoietic stem cell compartment. Nat Rev Immunol 2013, 13:376-389.
26. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell 2013, 153(1):17-37.
27. Frank S.A., Nowak M.A. Cell biology: Developmental predisposition to cancer. Nature 2003, 422:494.
28. Snape K., Hanks S., Ruark E., et al. Mutations in CEP57 cause mosaic variegated aneuploidy syndrome. Nat Genet 2011, 43:527-529.
29. Rio Frio T., Lavoie J., Hamel N., et al. Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. N Engl J Med 2010, 363:2628-2637.
30. Mouret S., Baudouin C., Charveron M., Favier A., Cadet J., Douki T. Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. Proc Natl Acad Sci U S A 2006, 103:13765-13770.
31. United Nations Scientific Committee on the Effects of Atomic Radiation. Effects of ionizing radiation. United Nations. New York. 2008.
32. Rossner P., Svecova V., Schmuczerova J., et al. Analysis of biomarkers in a Czech population exposed to heavy air pollution. Part I: bulky DNA adducts. Mutagenesis 2013, 28:89-95.
33. Jantzen K., Roursgaard M., Desler C., Loft S., Rasmussen L.J., Moller P. Oxidative damage to DNA by diesel exhaust particle exposure in co-cultures of human lung epithelial cells and macrophages. Mutagenesis 2012, 27:693-701.
34. Phillips D.H., Venitt S. DNA and protein adducts in human tissues resulting from exposure to tobacco smoke. Int J Cancer 2012, 131:2733-2753.
35. Tung E.W., Philbrook N.A., Macdonald K.D., Winn L.M. DNA double-strand breaks and DNA recombination in benzene metabolite-induced genotoxicity. Toxicol Sci 2012, 126(2):569-577.
36. Costa C., Costa S., Silva S., et al. DNA damage and susceptibility assessment in industrial workers exposed to styrene. J Toxicol Environ Health A 2012, 75:735-746.
37. Lyon M.F. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 1961, 190:372-373.
38. Ohno S., Hauschka T.S. Allocycly of the X-chromosome in tumors and normal tissues. Cancer Res 1960, 20:541-545.
39. Caspersson T., Farber S., Foley G.E., et al. Chemical differentiation along metaphase chromosomes. Exp Cell Res 1968, 49:219-222.
40. Caspersson T., Zech L., Johansson C. Analysis of human metaphase chromosome set by aid of DNA-binding fluorescent agents. Exp Cell Res 1970, 62:490-492.
41. Latt S.A. Optical studies of metaphase chromosome organization. Annu Rev Biophys Bioeng 1976, 5:1-37.
42. Schreck RR, Disteche CM. Chromosome banding techniques. Curr Protoc Hum Genet. 2001 May;Chapter 4: Unit 4.2.
43. Langer-Safer P.R., Levine M., Ward D.C. Immunological method for mapping genes on Drosophila polytene chromosomes. Proc Natl Acad Sci U S A 1982, 79:4381-4385.
44. Schrock E., du Manoir S., Veldman T., et al. Multicolor spectral karyotyping of human chromosomes. Science 1996, 273:494-497.
45. Saiki R.K., Gelfand D.H., Stoffel S., et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239:487-491.
46. Schouten J.P., McElgunn C.J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002, 30:e57.
47. Porcher C., Malinge M.C., Picat C., Grandchamp B. A simplified method for determination of specific DNA or RNA copy number using quantitative PCR and an automatic DNA sequencer. Biotechniques 1992, 13:106-114.
48. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977, 74:5463-5467.
49. Pinkel D., Segraves R., Sudar D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998, 20:207-211.
50. Carter N.P. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 2007, 39:S16-S21.
51. DeScipio C., Spinner N.B., Kaur M., et al. Fine-mapping subtelomeric deletions and duplications by comparative genomic hybridization in 42 individuals. Am J Med Genet A 2008, 146:730-739.
52. Rabin K.R., Man T.K., Yu A., et al. Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2008, 51:171-177.
53. HH T. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 1938, 23:566-574.
54. Sybert V.P., McCauley E. Turner's syndrome. N Engl J Med 2004, 351:1227-1238.
55. Papoulidis I., Kontodiou M., Tzimina M., et al. Tetrasomy 9p mosaicism associated with a normal phenotype in two cases. Cytogenet Genome Res 2012, 136:237-241.
56. McAuliffe F., Winsor E.J., Chitayat D. Tetrasomy 9p mosaicism associated with a normal phenotype. Fetal Diagn Ther 2005, 20:219-222.
57. Di Giacomo M.C., Susca F.C., Resta N., Bukvic N., Vimercati A., Guanti G. Trisomy 13 mosaicism in a phenotypically normal child: description of cytogenetic and clinical findings from early pregnancy beyond 2 years of age. Am J Med Genet A 2007, 143:518-520.
58. Aypar E., Yildirim M.S., Sert A., Ciftci I., Odabas D. A girl with metopic synostosis and trisomy 13 mosaicism: case report and review of the literature. Am J Med Genet A 2011, 155:638-641.
59. Lorda-Sanchez I., Villa A., Urioste M., et al. Tetrasomy 5p mosaicism due to an extra i(5p) in a severely affected girl. Am J Med Genet 1997, 68:481-484.
60. Venci A., Bettio D. Tetrasomy 5p mosaicism due to an additional isochromosome 5p in a man with normal phenotype. Am J Med Genet A 2009, 149:2889-2891.
61. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
62. Stilgenbauer S., Nickolenko J., Wilhelm J., et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene 1998, 16:1891-1897.
63. Happle R. Cutaneous manifestation of lethal genes. Hum Genet 1986, 72:280.
64. Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet 1986, 29:321-324.
65. McCune D.J. Osteitis fibrosa cystica: the case of a nine-year-old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child 1936, 52:743-744.
66. Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation, and endocrine dysfunction, with precocious puberty in females: report of 5 cases. N Engl J Med. 1937;216:727-46.
67. Weinstein L.S., Shenker A., Gejman P.V., Merino M.J., Friedman E., Spiegel A.M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991, 325:1688-1695.
68. Schwindinger W.F., Francomano C.A., Levine M.A. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A 1992, 89:5152-5156.
69. Collins M.T., Sarlis N.J., Merino M.J., et al. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab 2003, 88:4413-4417.
70. Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989, 340:692-696.
71. Biesecker L.G. The multifaceted challenges of Proteus syndrome. JAMA 2001, 285:2240-2243.
72. Lindhurst M.J., Sapp J.C., Teer J.K., et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011, 365:611-619.
73. Hers I., Vincent E.E., Tavare J.M. Akt signalling in health and disease. Cell Signal 2011, 23:1515-1527.
74. Janoueix-Lerosey I., Lequin D., Brugieres L., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
75. George R.E., Sanda T., Hanna M., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
76. Chen Y., Takita J., Choi Y.L., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
77. Choi Y.L., Takeuchi K., Soda M., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008, 68:4971-4976.
78. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
79. Amary M.F., Damato S., Halai D., et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011, 43:1262-1265.
80. Pansuriya T.C., van Eijk R., d'Adamo P., et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011, 43:1256-1261.
81. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
82. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010, 16:387-397.
83. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
84. Groesser L., Herschberger E., Ruetten A., et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 2012, 44:783-787.
85. Hafner C., Toll A., Gantner S., et al. Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet 2012, 49:249-253.
86. Bourdeaut F., Herault A., Gentien D., et al. Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. J Med Genet 2010, 47:859-862.
87. Hafner C., Toll A., Real F.X. HRAS mutation mosaicism causing urothelial cancer and epidermal nevus. N Engl J Med 2011, 365:1940-1942.
88. Hafner C., Groesser L. Mosaic RASopathies. Cell Cycle 2013, 12:43-50.
89. Sahin E., Depinho R.A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010, 464:520-528.
90. Hedrick P.W. Sex: differences in mutation, recombination, selection, gene flow, and genetic drift. Evolution 2007, 61:2750-2771.
91. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
92. Walter M.J., Shen D., Ding L., et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012, 366:1090-1098.
93. Bonnefond A., Skrobek B., Lobbens S., et al. Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat Genet 2013, 45:1040-1043.
94. Forbes S.A., Bindal N., Bamford S., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011, 39:D945-D950.
95. Consortium E.P., Bernstein B.E., Birney E., et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74.
96. Chanock S. Toward mapping the biology of the genome. Genome Res 2012, 22(9):1612-1615.
97. Chiang D.Y., Getz G., Jaffe D.B., et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods 2009, 6:99-103.
98. Lawrence M.S., Stojanov P., Polak P., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
99. Sathirapongsasuti J.F., Lee H., Horst B.A., et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 2011, 27:2648-2654.
100. Koboldt D.C., Zhang Q., Larson D.E., et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012, 22:568-576.
101. Yoon S., Xuan Z., Makarov V., Ye K., Sebat J. Sensitive and accurate detection of copy number variants using read depth of coverage. Genome Res 2009, 19:1586-1592.
102. Abyzov A., Urban A.E., Snyder M., Gerstein M. CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res 2011, 21:974-984.